Status:
COMPLETED
Effects of A Standardized Treatment Approach on Kidney Transplant Recipients With Antibody-Mediated Rejection
Lead Sponsor:
Istanbul University
Conditions:
Antibody-mediated Rejection
Kidney Transplant Rejection
Eligibility:
All Genders
18+ years
Brief Summary
Antibody-mediated rejection (ABMR) is one of the leading causes of graft loss in kidney transplant recipients (KTRs). Although it is a well characterized entity, there is limited data regarding effect...
Eligibility Criteria
Inclusion
- Being a kidney transplant recipient with biopsy-proven acute or chronic antibody-mediated rejection who were treated using 6 sessions of therapeutic plasma exchange, 2 g/kg of intravenous immunoglobulin and 1-2 weekly doses of 375 mg/m2 rituximab.
Exclusion
- Not providing or withdrawing consent.
Key Trial Info
Start Date :
September 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2020
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT04367610
Start Date
September 1 2019
End Date
December 31 2020
Last Update
May 18 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istanbul University
Istanbul, Turkey (Türkiye)